Anti-Inflammatory Therapies in Coronary Artery Disease; A Systematic Review

Authors: de Courcy, Louis; Moore, Jack

Source journal: Clinical cardiology (2026-11-01)

DOI: 10.1002/clc.70519

Abstract

AIMS: Pro-inflammatory cytokines play an important role in multiple facets of coronary artery disease (CAD), from endothelial dysfunction to plaque development and rupture to reperfusion injury post-revascularisation. We aimed to identify and present key data from randomized controlled trials (RCTs) which investigate anti-inflammatory drugs with the goal of improving outcomes associated with CAD. METHODS AND RESULTS: We searched for placebo-controlled RCTs across three databases (Cochrane Library, PubMed, and ClinicalTrials.gov) using the terms "anti-inflammatory" and "coronary artery disease" as well as variants. Thirty-three studies were identified and categorized as: (a) secondary prevention of major adverse cardiovascular events (MACE), (b) secondary prevention of radiographic evidence of CAD, and (c) reduction in reperfusion injury when administered during reperfusion. Seven trials demonstrated a reduction in CAD, including five phase III trials for secondary prevention of MACE. CONCLUSION: The majority of anti-inflammatory therapies did not show improved outcomes across a variety of endpoints. However colchicine and canakinumab have shown benefit in reducing MACE in phase III trials, while tocilizumab improved myocardial salvage index when administered peri-reperfusion. These findings suggest that the NLRP3-IL1beta-IL6-CRP pathway may represent a promising therapeutic target and an important focus for future research in CAD prevention, particularly in patients with high residual inflammatory risk.

Read the full text

Related topics

Related open access articles

Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.